“Medice, cura te ipsum” Doctor, heal yourself. Even healers burn out. Rest is not weakness, it is repair. Caring for others starts with caring for yourself. @oncoalert.bsky.social @oncbrothers.bsky.social @ascocancer.bsky.social @myesmo.bsky.social

Dr. Yüksel Ürün’s Highlights from VIRO 2025 on Personalizing Treatment in the Frontline Setting @yukselurun.bsky.social oncodaily.com/pulse/dr-yuk... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #VIRO #VIRO25

Join Us for Global Voices in Renal Oncology Virtual Congress 2025 @yukselurun.bsky.social oncodaily.com/pulse/global... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Global voices, shared hope. Excited to join colleagues at VIRO 2025—working together for patients in renal cancer. #OncoDaily #VIRO2025 @oncodaily.bsky.social docs.google.com/forms/d/e/1F...

🌍 𝗚𝗹𝗼𝗯𝗮𝗹 𝗩𝗼𝗶𝗰𝗲𝘀 𝗶𝗻 𝗥𝗲𝗻𝗮𝗹 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 (𝗩𝗜𝗥𝗢) 𝗩𝗶𝗿𝘁𝘂𝗮𝗹 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 📅 Sept 11–12, 2025 | 🩺 Chaired by Dr. Rana McKay & co-chaired by Dr. Yüksel Ürün @yukselurun.bsky.social 🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗳𝗿𝗲𝗲: forms.gle/qcQyaGMQfHDh... oncodaily.com/pulse/rana-m... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd

Meet the Experts of VIRO 2025 - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/pulse/yuksel... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Liquid Biopsy Is No Longer the Future - Yüksel Ürün @yukselurun.bsky.social @neerajagarwal.bsky.social @euplatinum.bsky.social oncodaily.com/science/liqu... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LiquidBiopsy

Cancer Prevention is the Quiet Revolution - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/voices/yukse... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Every patient teaches me something new about strength, hope, and why we fight.

Science Is Better When It’s Shared - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/blog/science... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Science

Breast Cancer Care Shouldn’t Be a Luxury - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/insight/yuks... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer

This sounds like an exciting step forward! How soon do you think cancer vaccines like these could become more widely used?

A Promising Option for Non–Non-Clear-Cell Renal Cell Carcinoma - Yüksel Ürün @yukselurun.bsky.social @euplatinum.bsky.social oncodaily.com/science/yuks... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #nccRCC #KidneyCancer

How Should We Treat mCRPC and HRR Deficiency? - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/blog/how-sho... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #mCRPC #HRR #ProstateCancer

First Positive Phase 3 Trial for a Bispecific ADC - Paolo Tarantino @ptarantinomd.bsky.social @yukselurun.bsky.social oncodaily.com/insight/paol... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADC

Cancer vaccines: the next frontier is now. From HBV & HPV to personalized mRNA shots @oncoalert.bsky.social @oncoassist.bsky.social @ptarantinomd.bsky.social @drchoueiri.bsky.social @viveksubbiah.bsky.social

Take care of your kidneys, protect your life. 4 simple actions = less risk, better outcomes: 🚭 Quit smoking ⚖️ Stay at a healthy weight 🏃‍♀️ Be active, avoid trauma 💧 Drink water, skip alcohol Because prevention is power @oncoalert.bsky.social @drchoueiri.bsky.social @kidneycan.bsky.social

🎗 Gerçek bilim bazen zor konuşur. Herkes “mucize” ister, ama biz sabırla örülmüş gerçekleri anlatırız. 📌 Evet, süreç yorucu. 📌 Evet, sonuç her zaman adil değil. Ama geçmişe göre çok daha iyiyiz. Birçok tümörde, yıllar kazandıran tedaviler var artık

Bugünkü kelimemiz: Radikal Prostatektomi 🧬 Prostat kanseri tedavisinde sık kullanılan bu kelime, aslında ne demek? 👨‍⚕️ Prostat bezinin tamamen çıkarıldığı bir ameliyat. Genellikle erken evredeki hastalarda uygulanır. 🎯 Bilmek güç verir. Takipte kalın, diğer terimleri de birlikte öğrenelim.

🔬 Klinik Araştırma Nedir? Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır. Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar, hem de gelecekte binlerce hayatın değişmesine katkı sağlar. #science

Biyopsi = Şüpheli dokudan parça alıp mikroskopla incelemek. Örneğin: “Mesanedeki kitlenin ne olduğunu anlamak için biyopsi yapıldı.” 🎯 Çünkü doğru tanı, doğru tedavinin ilk adımıdır.

I have two favourite studies from #ASCO25 @christielibrary.bsky.social @mcrcnews.bsky.social 👇🏽 www.nejm.org/doi/full/10....

Our new JAMA Cardiology study finds that many US adults don't know that they have hypertension, diabetes, or high cholesterol Nearly 1 in 3 young adults w/ hypertension, 2 in 5 with diabetes, and 1 in 4 with high cholesterol are unaware of their condition. bit.ly/45an6MC #medsky #cardiosky

#ASMS2025 ThP046 come to check out Jenny’s poster! Don’t miss this great opportunity to meet Jenny! @asms.org @jyates.bsky.social @femalesinms.bsky.social #teammassspec @garcialabms.bsky.social @proteomicsnews.bsky.social

This is so true. We have to continually work together to get better #healthcare delivery & #research advances to ALL #patients.

Every oncologist is a patient advocate. Right treatment. Right time. For every patient. #ASCO25 #Oncology #CancerCare #AccessMatters @oncoalert.bsky.social @ascocancer.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social @oncbrothers.bsky.social

Thrilled to share our new analysis from CheckMate 901! 🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS and OS. ➡️A new horizon for a distinct subgroup. @uroweb.org @oncoalert.bsky.social @oncbrothers.bsky.social

📢 Just in: Multivitamins after MI in diabetes? 🔬 In this RCT (n=1000), oral multivitamins didn't reduce CV events after MI in patients with diabetes. 🎯 35% event rate in both arms HR: 0.99 No benefit. #Cardiology #Diabetes #RCT #JAMA

Longitudinal ctDNA profiling in mCRPC reveals how Tumors evolve - Yüksel Ürün @yukselurun.bsky.social oncodaily.com/science/yuks... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ctDNA #mCRPC #ProstateCancer

New era for HER2-mutant lung cancer! Zongertinib delivered a 71% response rate, 12.4 months median PFS! No ILD reported. Precision hitting its mark! #LungCancer #Oncology #Targeted #cancerresearch @nejm.org @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social

Abstracts are out for #ASCO25! 5000+ studies. 5 Plenary game-changers. @ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social

The ESMO Research Fellowship is now open. A chance to dive deep into science, grow globally, and shape the future of cancer care. Ready to make impact? @myesmo.bsky.social @oncoalert.bsky.social @ptarantinomd.bsky.social @antoniopassaro.bsky.social @drchoueiri.bsky.social

Many kudos to @ascocancer.bsky.social amazing #SoMe staff for putting together this great highlight of #ASCO25 planning. Getting a moment to hang with the real stars 🤩 inc @ryannipp.bsky.social and my #MedEd colleagues. Looking forward to May in Chicago 🌃

Thrilled to announce that our article has been selected as a Top Viewed Article in Cancer journal! “Cancer-associated thrombosis and drug–drug interactions of antithrombotic/antineoplastic agents” Thank you for reading, sharing making science matter @oncoalert.bsky.social @ascocancer.bsky.social

Grateful to be included on this list alongside such great minds as Dr @yukselurun.bsky.social Much appreciated, @Larvol 😊

What if we screened smarter, not just more? In BARCODE1, men with high polygenic risk (top 10%) had MRI + biopsy— 40% had prostate cancer. Over half needed treatment. Most would’ve been missed by PSA alone. Genetics is rewriting the rules. @nejm.org @myesmo.bsky.social @oncoalert.bsky.social

🧬 Genomic testing in childhood & young adult cancers: 🧬16–18% carry germline variants 🧬Somatic findings guide Dx in up to 95% 🧬Matched therapy? Often possible—rarely given The science is ready. Let’s make care catch up. @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social

🧬 Bigger isn’t always better— In this randomized trial, a large 324-gene panel (F1CDX) identified more matched therapies vs. a smaller panel (51.6% vs 36.9%, +14.8%) But… no survival benefit seen. More targets ≠ better outcomes—yet. @oncoalert.bsky.social @viveksubbiah.bsky.social rdcu.be/egWk9

I’m always inspired by the brilliant minds on this list (and many others!) who generously share insights and push the field of oncology forward. Grateful to @larvol for the inclusion. @ascocancer.bsky.social

Can a shingles vaccine protect the brain? Zoster vaccination linked to a 20% lower risk of dementia over 7 years. @nature.com rdcu.be/egydp

TIL therapy + pembrolizumab (SEL-TIL + P) shows 23.5% response in mismatch repair–proficient GI cancers—where immunotherapy usually fails. Neoantigen recognition may be the key. @oncoalert.bsky.social @nature.com @viveksubbiah.bsky.social @jameabraham.bsky.social

Big congrats to Dr. Hatice Bölek! Proud mentor moment! Together, we can—and will—improve the quality of life for every patient facing cancer. #IKCC25 #KidneyCancer #Oncology #PatientCare @kidney-cancer.bsky.social @ikccorg.bsky.social @kidneycan.bsky.social @oncoalert.bsky.social

Great opportunity to meet and discuss real world PROs, QoL for patients with metastatic #kidneycancer in Turkiye. Impressive data on patient experiences thanks to @yukselurun.bsky.social and colleagues #ikcc25

Plato: “Ivermectin—why not give it a try?” Aristotle: “Maybe because tumors aren’t worms.” #cancer #Oncology

Next-gen precision oncology in action. OncoIncytes: visualizing PD-L1 & HER2 expression in CTCs— real-time mutation tracking. From slides to survival. The future is cell-deep. #LiquidBiopsy #CancerResearch @oncoalert.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social

Learning from the best. @Dr_R_Kurzrock breaks new ground! 🧬From tissue biopsy to cell biopsy. From fragments to full stories—CTCs, ctDNA, proteomics, transcriptomics. 1080 genes. One goal: precision for every patient. @oncoalert.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social

What I’m good at: -Prostate, -Bladder, -Kidney, -Testicular cancer What my family asks me about: -“Is this mole cancer?” -“I read turmeric cures cancer—thoughts?” -“My back hurts, should I be worried?” -“Is my horoscope linked to cancer risk?” #cancer #oncology

MRD and Beyond: Rethinking Cancer Surveillance 90% of cancer-related deaths come from metastatic disease—often years after resecting the primary tumor. Biomarkers can change the game. Early detection = earlier action = better outcomes. Time to track the invisible. @oncoalert.bsky.social @islb.info

Navigating the future of #LiquidBiopsy with @christianrolfo.bsky.social at #poles25 From screening to resistance tracking—MRD is reshaping how we detect, treat, and monitor cancer. Tissue vs liquid? It’s not a battle—it’s a partnership. @rolfolab.bsky.social @islb.info @oncoalert.bsky.social

Global cancer care shouldn’t depend on your ZIP code. Equity. AI-powered precision. Collaboration across patients, providers, pharma & payers. Presented by Mr. Mohan Uttarwar Let’s bridge the gap, together. #Oncology #CancerCare #Equity @oncoalert.bsky.social @ascocancer.bsky.social